Lexicon Pharmaceuticals (LXRX) EBT Margin (2010 - 2026)
Lexicon Pharmaceuticals (LXRX) posted quarterly EBT Margin of 25.1% for Q1 2026, up 224487.0% year-over-year from N/an in Q1 2025, and up 91.8% quarter-over-quarter from 306.04% in Q4 2025.
Powered by 
Analysis
Lexicon Pharmaceuticals (LXRX) EBT Margin (2010 - 2026) Analysis & Trends
Lexicon Pharmaceuticals (LXRX) has reported EBT Margin for 16 consecutive years, with 25.1% the latest figure, recorded in Q1 2026.
- In Q1 2026, EBT Margin rose 224487.0% year-over-year to 25.1%; the TTM figure through Mar 2026 stood at 61.69% (up 55043.0% YoY), while the FY2025 annual figure was 121.59%, up 186692.0% from the prior year.
- EBT Margin climbed to 25.1% in Q1 2026 per LXRX's latest filing, from 306.04% in the prior quarter.
- Across five years, EBT Margin topped out at 14.45% in Q2 2025 and bottomed at 74708.57% in Q2 2022.
- Historically, EBT Margin has averaged 11628.42% across 5 years, with a median of 3495.14% in 2024.
- Annual changes were most pronounced in 2023 — EBT Margin soared 5705324 bps — and 2025, when it plunged 16823 bps.
- Lexicon Pharmaceuticals' EBT Margin stood at 74708.57% in 2022, then jumped by 91 bps to 6928.33% in 2023, then jumped by 98 bps to 137.81% in 2024, then slumped by 122 bps to 306.04% in 2025, then jumped by 92 bps to 25.1% in 2026.
- Business Quant data shows LXRX's EBT Margin at 25.1% in Q1 2026, 306.04% in Q4 2025, and 117.66% in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 41.75% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 35.61% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 35.78% |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -528.97% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 18.33% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 13.77% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 12.09% |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -2.67% |
| 10 | Lexicon Pharmaceuticals | 978.15 Mn | 787.54 Mn | 653,000.00 | -4,212.28% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -4,212.28% |
| Mar 31, 2026 | -12.25% |
| Dec 31, 2025 | -306.04% |
| Sep 30, 2025 | -101.13% |
| Jun 30, 2025 | 4.91% |
| Mar 31, 2025 | -2,180.19% |
| Dec 31, 2024 | -137.81% |
| Sep 30, 2024 | -3,900.29% |
| Jun 30, 2024 | -3,495.14% |
| Mar 31, 2024 | -4,449.65% |
| Dec 31, 2023 | -7,429.91% |
| Sep 30, 2023 | -33,043.21% |
| Jun 30, 2023 | -14,554.26% |
| Mar 31, 2023 | -136,241.67% |
| Dec 31, 2022 | -111,850.00% |
| Sep 30, 2022 | -62,307.69% |
| Jun 30, 2022 | -70,922.86% |
| Dec 31, 2021 | -183,071.43% |
| Sep 30, 2021 | -100,582.61% |
| Jun 30, 2021 | -7,751.28% |